NATURAL NEWS

NIH defies FOIA, vaxx royalty data remains shrouded in secrecy

“The very word ‘secrecy’ is repugnant in a free and open society; and we are as a people inherently and historically opposed to secret societies, to secret oaths and to secret proceedings... We are opposed around the world by a monolithic and ruthless conspiracy that relies primarily on covert means for expanding its sphere of influence–on infiltration instead of invasion, on subversion instead of elections, on intimidation instead of free choice, on guerrillas by night instead of armies by day. It is a system which has conscripted vast human and material resources into the building of a tightly knit, highly efficient machine that combines military, diplomatic, intelligence, economic, scientific and political operations. Its preparations are concealed, not published. Its mistakes are buried, not headlined. Its dissenters are silenced, not praised. No expenditure is questioned, no rumor is printed, no secret is revealed.” -John F. Kennedy (assassinated)

“The U.S. National Institutes of Health (NIH) is refusing to release additional information about an agreement it reached over a COVID-19 vaccine that has earned it at least $400 million. The NIH declined to provide any materials in response to a Freedom of Information Act request from The Epoch Times. ‘The NIH withholds the entirety of the records as they are protected from release,’ Gorka Garcia-Malene, an NIH officer, told The Epoch Times in a letter. She cited an exemption outlined in the act that allows government agencies to partially or fully withhold information. ‘In this case, exemption 3 incorporates 35 U.S.C. 209 (f), which reads in relevant part, ‘No Federal agency shall grant any license under a patent or patent application on a federally owned invention unless the person requesting the license has supplied the agency with a plan for development or marketing of the invention, except that any such plan shall be treated by the Federal agency as commercial and financial information obtained from a person and privileged and confidential and not subject to disclosure under section 552 of title 5,’’ Ms. Garcia-Malene wrote. ‘Exemption 4 protects from disclosure trade secrets and commercial or financial information that is privileged and confidential,’ she added.”